3 measurements spanning 7 days, net +8. Dots are measurements; the straight line between them is drawn to join them, not to claim we know the path taken in between — snapshots are recorded only when a count changes, so gaps mean “no change observed”, never “interpolated”. The vertical axis spans 93–103 and does not start at zero.
Measurement log — every subscribers count we have recorded
Measured (UTC)
Subscribers
Change
17 Aug 2026, 11:58
102
+8
10 Aug 2026, 23:52
94
no change
10 Aug 2026, 01:30
94
first reading
Engagement
20 posts held, back to 4 August 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 1 pageof Telegram’s post history, 20 posts per page.
ERR · 30 days
223.2%
avg views ÷ 102 subscribers
Avg views / post
228
20 posts measured
Reaction rate
2.37%
reactions ÷ views · ER floor
Posts in window
20
of 20 held
ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.
ER is defined industry-wide as (forwards + reactions + comments) ÷ views— note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate.
What these figures were computed from
Window
Rolling 30 days · latest post in window 9 August 2026
Posts held
20 (4 August 2026 – 9 August 2026)
Views total
4,554
Reactions total
108
Forwards / comments
not exposed by the public surface — not measured, not estimated
Readings taken
10 Aug 2026, 01:30 UTC
Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.
Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.
Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.
Reaction mix
108 reactions across 20 posts, in 14 distinct kinds. The most used accounts for 48.1% of them.
Every reaction kind recorded on the sample, most used first
Reaction
Count
Share
Share, drawn
👍
52
48.1%
❤
19
17.6%
👏
18
16.7%
💯
3
2.78%
🤔
3
2.78%
😁
2
1.85%
🙏
2
1.85%
🤓
2
1.85%
🤗
2
1.85%
🆒
1
0.926%
👌
1
0.926%
😍
1
0.926%
😐
1
0.926%
🤩
1
0.926%
No sentiment is inferred, and none should be read in. This table is ordered by count and by nothing else. Emoji do not carry stable meaning across languages or communities — 🙏 is thanks in one channel and mourning in another — so we publish which ones were pressed and how often, and pass no judgement on what an audience meant by them.
Precision. Telegram publishes reaction counts per emoji and short-forms each one — 4.34K, 1.2M — so any single kind at or above 1,000 reaches us at three significant figures, and only counts below 1,000 are exact. The shares above are ratios of those figures and carry the same error. This is also why the total here can differ slightly from a reaction total printed elsewhere on the page: both are sums of the same rounded parts, taken over samples with different edges.
Coverage. Reactions were read on 20 of the 20 sampled posts in this sample. Summed by Telegram’s own count on each post — not by adding up the per-emoji breakdown above — those same posts carry 108reactions in total: the kind of figure the paragraph above means by “a reaction total printed elsewhere on the page”.
Measured over the 20 most recent posts we hold, published 4 August 2026 to 9 August 2026, using the newest reading held for each. Telegram Stars are excluded: they are a payment, not a reaction, and they have their own section.
1. 일라이 릴리의 "터제파타이드 고용량(Higher Doses)"은 20/25 mg임을 증명함
2. 일라이 릴리의 파이프라인 중에서 터제파타이드 고용량(Higher Doses)이 있음
3. 일각에서는 공식적으로 알려진 최대 용량인 "15 mg"이라고 하지만 본인은 아니라고 생각함
4. COFEPRIS에서 15/20/25 mg 실제 시험용량을 확인했고, 일라이 릴리의 특허(WO2024006662A1)에서 15→20→25 mg이라는 실제 higher-dose regimen(투여 요법)을 확인했기 때문에 I8F-MC-GPIT에서 실제 연구된 터제파타이드 용량은 15 mg, 20 mg, 25 mg이라고 생각함
5. "월 1회" 기준으로 요구되는 약물(터제파타이드 고용량)을 담아내기 위해 필요한 미립구 질량이 실용적인 SC 한계의 상단인 40…
1. 노보노디스크의 CFO 카르스텐 뭉크 크누드센은 피어스(Fierce)와의 인터뷰에서 회사의 변화하는 상황 속에서 길을 찾는 것은 "많은 압박감"을 수반하며 올바른 결정을 내려야 할 책임감이 따른다고 말했음
2. 경구용 위고비의 판매가 호조를 보인 가운데, 향후 성장을 견인할 주요 요인 중 하나는 카그리세마(CagriSema)가 될 것으로 예상했음
3. 최근 카그리세마에 대한 엇갈린 데이터가 나왔음에도 불구하고, 크누드센은 FDA 승인 결정을 앞두고 해당 치료법의 전망에 대해 "여전히 낙관적"이라고 강조함
4. 비록 결과가 릴리의 터제파타이드와 일치하지는 않았지만, HbA1c 수치가 1.9%포인트 감소한 것은 "실제로 매우 좋은 혈당 강하 효과"를 나타내는 것이며, 환자들의 체중이 15.2% 감소한 것은 "매우 긍정적인 결과"라고 말…
1. 아밀린/근손실방지제/PYY/FGF와의 병용 가능성을 표시한 것의 의미를 생각해봄
2. (GLP-1/GIP/GCG)와 (아밀린/근손실방지제/PYY/FGF)를 병용할 때에, 아밀린/근손실방지제/PYY/FGF의 투여용량, 투여주기를 고려해서 병용을 해야함
3. 지투지바이오 독자적으로 아밀린/근손실방지제/PYY/FGF의 투여용량, 투여주기를 고려해서 진행할 수 있을까?
4. 빅파마가 아밀린/근손실방지제/PYY/FGF의 투여용량, 투여주기를 알려주고 테스트를 시켰다는 것이 훨씬 더 합리적임
5. 아밀린/근손실방지제/PYY/FGF를 소유한 빅파마는 전세계에 그렇게 많지 않음
6. 그렇다면, 아밀린/근손실방지제/PYY/FGF를 소유한 빅파마를 역추적하면 현재 지투지바이오와 진행중인 빅파마를 찾는건 시간문제임
7. 아밀린을 소유한 빅파마는 …
1. 다중작용제와 병용이 대세가 되어갈 비만 시장
2. 다중작용제와 병용의 시대에서 미립구 회사의 역할은?
3. 다중작용제와 병용의 시대에 고농축 sc 항체 회사의 역할은?
4. 미립구 기술과 고농축 sc 항체 기술을 어떻게 융합해야 할까?
5. 아직은 먼 미래일까? 아니면 시작 되었을까?
6. 투자 관점에서, 알테오젠을 사야할까? 펩트론을 사야할까? 아니면 2개를 다하고 있는 지투지바이오를 사야할까?
7. 확인하고 들어갈래? 아니면 미리 들어가서 선점할래? 투자자는 항상 헷갈림
8. 지투지바이오는 올해안에 대기중인 이벤트가 너무 너무 많음
9. 그 속에서 지투지바이오는 공시를 몇개나 보여줄 수 있을까?
10. 다음주 바이오가 너무 기대되고, 지투지바이오의 상승이 제일 기대됨
1. GSK는 현재 FGF21(efimosfermin alfa)와 siRNA(Gatuzosiran)를 각각 독립적인 자산으로 개발하는 것을 넘어, 병용 전략을 핵심 대사질환(MASH/비만) 전략으로 보고 있음
2. MASH와 관련된 병용 사례
① 레즈디프라(최초로 승인된 MASH 치료제) + siRNA(리보 및 자회사 리보큐어 물질)
② Tirzepatide(GLP-1/GIP 이중 작용제) + siRNA(ARO-INHBE)
③ FGF21(efimosfermin alfa) + siRNA(Gatuzosiran)
3. 인크레틴 기반 약물/siRNA/FGF21를 병용하기 위해서는 장기지속형 기술과 초고농축 항체 SC 기술이 절대적으로 필요할 것이고, 2개 동력(초고농축 항체 SC 기술/장기지속형 기술)을 지투지바이오가 모두 가지고 있기…
1. 이희용 대표님이 발표 자료에 PYY를 그냥 쓰셨을까?
2. 다른 기업도 하는거 같으니.. 우리도 한번 집어넣어서 발표해보자
3. 절대 그러실 분이 아님. 이미 빅파마와 진행하고 있는 공동개발의 물질에 포함이 되어 있으니 적으셨다고 생각함
4. 이희용 대표님.. 미립구 1개만 30년동안 지대로 파신 전세계 미립구 1인자여!!!!!
1. PYY(NPY2R)는 일라이릴리/베링거인겔하임/노보노디스크가 연구하고 있었음
2. 노보노디스크는 연구를 현재는 하고 있지 않음
3. 베링거인겔하임이 PYY(NPY2R)를 포함한 3중작용제를 지투지바이오와 공동개발하고 있다고 생각함
4. 셀트리온의 4중작용제가 "GLP-1 + GIP + GCG + PYY" 조합이 맞다면, 셀트리온은 일라이릴리의 차세대물질과 PYY의 조합인 "레타트루타이드 + PYY"와 유사한 타깃을 노린다고 볼 수 있음
5. PYY(NPY2R) 물질이 그렇게 가볍게 볼 물질은 아니라는 생각이 듬
6. PYY(NPY2R)가 베링거/릴리/셀트리온과 연관이 있고, 현재 지투지바이오가 관련이 매우 높은것으로 생각됨
https://blog.naver.com/dogdum/224367544382
질랜드파마를 시발점으로 추정한 베링거인겔하임과 지투지바이오가 공동개발하고 있는 물질 2개중 1개는 "서보두타이드"라고 생각함
https://blog.naver.com/dogdum/224336472191
❤1👍1💯1🤓1
Showing the 12 most recent of 20 posts we hold for @g2gbiolove. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Citation-graph rank
Citation-graph rank — 1,091,789 of 1,480,975entries in the measured graph. A weighted position computed from the forward and mention edges below — republished posts weigh more than named mentions — and recomputed periodically, over the whole graph. Published only as this ordinal position, never as a score: a position is a fact, and a score printed beside one channel’s name would read as a verdict this register does not make. The two counts beneath stay separate for the same reason mentions are never summed with forwards anywhere else on this page — a named-by count costs nothing to manufacture. The top 100 by this measure, or how it is computed.
Forward network
Republished by
Channels on the register that have forwarded this channel's posts into their own feed.
Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.
Cite this entry
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 17 August 2026 — this
entry's latest reading, not the date you are reading this.
“지투지바이오” (@g2gbiolove), 102 subscribers as measured 17 August 2026. Telegram Register, tgregister.com/channel/g2gbiolove.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.